Investors had high hopes for VIVUS' (NAS: VVUS) new anti-obesity drug Qsymia, but the drug debuted to lackluster sales -- and it's taking a toll on VIVUS' share price. Now, VIVUS is shifting its focus -- marketing not to the doctors who will be prescribing Qsymia, but directly to patients by offering a free trial. Does this shift represent a fundamentally different marketing approach for the company, and more importantly for investors, will it work? Health care analysts Max Macaluso and Brenton Flynn discuss this news in the following video.
The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies is looking to change everything. Newly approved drugs, including Qsymia, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand new premium research service. It's such an important story that we have our top health care writer on the job, so make sure to secure a copy today by clicking here now.
The article Will VIVUS' Strategy Jump-Start Sales? originally appeared on Fool.com.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool owns shares of Express Scripts. Motley Fool newsletter services recommend Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.